Skip to content

Study · Non-randomized trial · n = 9 · 1982

4 results

Evidence for an augmented glucagon dependence of hepatic glucose production in cirrhosis of the liver.

Keller U, Sonnenberg GE, Burckhardt D, Perruchoud A

The Journal of clinical endocrinology and metabolism1 May 1982Cited by 34 (Europe PMC)

PMID6120952 (opens in a new tab)DOI10.1210/jcem-54-5-961 (opens in a new tab)PepBankPUB-06120952
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    After 40 min of somatostatin and glucagon replacement, glucose production reached 412 +/- 68 mg/min in controls, significantly exceeding cirrhotic patients.

    In plain wordsWith somatostatin and glucagon replacement, glucose production increased more in controls than in cirrhotic patients.

    Peptide
    Glucagon
    Outcome
    IncreaseNet splanchnic glucose production in controls
    Study

    n = 9

    Comparator
    Cirrhotic patients receiving the same replacement
    Outcome group
    Glycemic control · Liver
    Studied dose
    150 ng/m2 . min · infusion · 40 minAs given in this study (human).

    Measurements

    Net splanchnic glucose production
    179 mg/min
    cirrhotics
    Net splanchnic glucose production
    412 mg/min
    controls

    Source sentences

    Summary
    NSGP increased after 40 min of SRIF and glucagon replacement to 179 +/- 33 mg/min in cirrhotics and significantly more, to 412 +/- 68 mg/min, in controls (P less than 0.01).
    1 context sentence
    Summary · context
    To assure that NSGP declined during SRIF infusion due to the fall of glucagon levels, SRIF was combined with a glucagon infusion at 150 ng/m2 . min in four cirrhotics and in five control subjects.
  2. 02HumanNon-randomized trialPharmacokinetics

    In control subjects receiving somatostatin, glucagon replacement elevated arterial glucagon to a mean of 559 pg/ml.

    In plain wordsIn control subjects receiving somatostatin, glucagon replacement raised arterial glucagon to a mean of 559 pg/ml.

    Peptide
    Glucagon
    Outcome
    IncreaseArterial glucagon during replacement in controls
    Study

    n = 5

    Outcome group
    Pharmacokinetics · Liver
    Studied dose
    150 ng/m2 . min · infusionAs given in this study (human).

    Measurements

    Arterial glucagon
    559 pg/ml
    controls

    Source sentences

    Summary
    Arterial glucagon levels were elevated to a mean of 650 pg/ml and 559 pg/ml in cirrhotics and controls, respectively.
    1 context sentence
    Summary · context
    To assure that NSGP declined during SRIF infusion due to the fall of glucagon levels, SRIF was combined with a glucagon infusion at 150 ng/m2 . min in four cirrhotics and in five control subjects.
  3. 03HumanNon-randomized trialPharmacokinetics

    In cirrhotic patients receiving somatostatin, glucagon replacement elevated arterial glucagon to a mean of 650 pg/ml.

    In plain wordsIn cirrhotic patients receiving somatostatin, glucagon replacement raised arterial glucagon to a mean of 650 pg/ml.

    Peptide
    Glucagon
    Outcome
    IncreaseArterial glucagon during replacement in cirrhosis
    Study

    n = 4

    Outcome group
    Pharmacokinetics · Liver
    Studied dose
    150 ng/m2 . min · infusionAs given in this study (human).

    Measurements

    Arterial glucagon
    650 pg/ml
    cirrhotics

    Source sentences

    Summary
    Arterial glucagon levels were elevated to a mean of 650 pg/ml and 559 pg/ml in cirrhotics and controls, respectively.
    1 context sentence
    Summary · context
    To assure that NSGP declined during SRIF infusion due to the fall of glucagon levels, SRIF was combined with a glucagon infusion at 150 ng/m2 . min in four cirrhotics and in five control subjects.
  4. 04HumanNon-randomized trialActivity measurement

    In cirrhotic patients, net splanchnic glucose production increased to 179 +/- 33 mg/min after 40 min of somatostatin and glucagon replacement.

    In plain wordsIn cirrhotic patients receiving somatostatin, glucose production increased to 179 +/- 33 mg/min after 40 min of glucagon replacement.

    Peptide
    Glucagon
    Outcome
    IncreaseNet splanchnic glucose production in cirrhosis
    Study

    n = 4

    Outcome group
    Glycemic control · Liver
    Studied dose
    150 ng/m2 . min · infusion · 40 minAs given in this study (human).

    Measurements

    Net splanchnic glucose production
    179 mg/min
    cirrhotics

    Source sentences

    Summary
    NSGP increased after 40 min of SRIF and glucagon replacement to 179 +/- 33 mg/min in cirrhotics and significantly more, to 412 +/- 68 mg/min, in controls (P less than 0.01).
    1 context sentence
    Summary · context
    To assure that NSGP declined during SRIF infusion due to the fall of glucagon levels, SRIF was combined with a glucagon infusion at 150 ng/m2 . min in four cirrhotics and in five control subjects.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.